Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$0.4 - $0.9 $9,622 - $21,650
24,056 New
24,056 $11,000
Q3 2021

Nov 15, 2021

SELL
$2.73 - $4.52 $80,742 - $133,683
-29,576 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.74 - $4.63 $81,038 - $136,936
29,576 New
29,576 $98,000
Q1 2021

May 17, 2021

SELL
$3.93 - $6.68 $137,498 - $233,713
-34,987 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$5.02 - $6.59 $163,797 - $215,025
-32,629 Reduced 48.26%
34,987 $184,000
Q3 2020

Nov 16, 2020

SELL
$5.41 - $8.67 $212,645 - $340,783
-39,306 Reduced 36.76%
67,616 $380,000
Q2 2020

Aug 14, 2020

BUY
$8.05 - $29.44 $44,307 - $162,037
5,504 Added 5.43%
106,922 $861,000
Q1 2020

May 14, 2020

BUY
$7.24 - $30.0 $734,266 - $3.04 Million
101,418 New
101,418 $1.3 Million

About NeuroBo Pharmaceuticals, Inc.


  • Ticker NRBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 888,693
  • Market Cap $2M
  • Description
  • NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the tr...
More about NRBO
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.